The incidence of malignant melanoma is growing rapidly worldwide and there is still no effective therapy for metastatic disease. This type of cancer is highly resistant to conventional DNA-damaging chemotherapeutics, and intense research has been dedicated for understanding the molecular pathways underlying chemoresistance. The Ras/mitogen-activated protein kinase (MAPK) signalling pathway is often deregulated in melanoma, which frequently harbours activating mutations in NRAS or BRAF. Herein, we demonstrate that the MAPK-activated protein kinase RSK (p90 ribosomal S6 kinase) contributes to melanoma chemoresistance by altering their response to chemotherapeutic agents. We find that RSK phosphorylates checkpoint kinase 1 (Chk1) at an inhibitory site, Ser280, both in vitro and in vivo. Our results indicate that RSK is the predominant protein kinase operating downstream of mitogens and oncogenes of the Ras/MAPK pathway, and consistent with this, we find that RSK constitutively phosphorylates Chk1 in melanoma. We show that RSK inhibition increases Chk1 activity in response to DNA-damaging agents, suggesting that the Ras/ MAPK pathway modulates Chk1 function and the response to DNA damage. Accordingly, we demonstrate that RSK promotes G2 DNA damage checkpoint silencing in a Chk1-dependent manner, and find that RSK inhibitors sensitize melanoma cells to DNA-damaging agents. Together, our results identify a novel link between the Ras/MAPK pathway and the DNA damage response, and suggest that RSK inhibitors may be used to modulate chemosensitivity, which is one of the major obstacles to melanoma treatment.
INTRODUCTION
The Ras/mitogen-activated protein kinase (MAPK) pathway has a central role in transducing extracellular signals to cellular target proteins involved in cell growth and proliferation (reviewed in Meloche and Pouyssegur, 1 Yoon and Seger, 2 Rubinfeld and Seger 3 ). Inappropriate regulation of this pathway leads to a variety of disorders and diseases, including many types of cancers. 4 In this pathway, the small GTPase Ras activates Raf isoforms, which are Ser/Thr kinases frequently mutated in human cancers, such as melanoma. 5, 6 In turn, activated Raf phosphorylates and activates MEK1/2, which are dual-specificity kinases capable of phosphorylating the MAPKs ERK1/2. Once activated, ERK1/2 phosphorylate several substrates including members of the p90 ribosomal S6 kinase (RSK) family of protein kinases. 7 The RSK family is comprised of four Ser/Thr kinases (RSK1-4) that are closely related to one another. 8 Inhibition of RSK activity in cell culture systems reduces cancer cell proliferation, [9] [10] [11] and accordingly, RSK1 and RSK2 are overexpressed or hyperactivated in several cancers 12 including melanoma. 13 Melanoma originates from pigment-producing melanocytes localized in the skin and around 160 000 new cases of the malignant disease are diagnosed each year. 14 Although melanoma accounts for only 4% of all dermatologic cancers, it is responsible for 80% of deaths from skin cancer. Indeed, only 14% of patients with metastatic melanoma survive for 5 years, as it is highly invasive and resistant to conventional chemotherapies. 15 From a molecular standpoint, oncogenic activation of the MAPK pathway, due to somatic mutations in NRAS or BRAF, is the earliest genotypic change observed in melanoma. 16 Mutation of BRAF to produce an activated BRaf kinase (V600E) occurs at a high frequency (466%) 17 and tumours harbouring this mutation are highly dependent on the MAPK pathway for their growth. 18, 19 Metastatic melanoma is characterized by no proven effective therapy and poor outcomes. 20 A fundamental cause of the limited efficacy of chemotherapy in advanced melanoma is associated with chemoresistance mechanisms. 15 The DNA alkylating agent dacarbazine (also called DTIC) is considered to be the reference therapy for metastatic melanoma, but it produces response rates of o10% and median progression-free survival times of 2 months. 21 Temozolomide (TMZ), an analogue of dacarbazine, and cisplatin have comparable clinical activity to DTIC, highlighting the urgent need for new therapeutic approaches. 22 More targeted therapies have been directed against key pathways in melanomagenesis, such as the Ras/MAPK pathway. Currently, a BRaf inhibitor (PLX4032) has shown impressive results in clinical trials, 23 but resistance has already been reported and the longterm survival benefit remains to be established. 24, 25 Drugs such as cisplatin have a consistent rate of initial responses, but treatment often results in the development of chemoresistance, leading to therapeutic failure. 26 The most prominent mode of action of cisplatin-like agents involves the sequential activation of the ataxia telangiectasia mutated-and RAD3-related protein (ATR), and the checkpoint kinase 1 (Chk1). 27 In response to DNA damage, Chk1 is preferentially phosphorylated 1 by ATR at multiple SQ/TQ motifs within its C-terminal regulatory domain, most notably at Ser317 and Ser345. Phosphorylation of these residues is essential for Chk1 biological activity. 28, 29 Activated Chk1 promotes the rapid degradation of the cdc25 phosphatase, leading to transient cell cycle arrest that allows DNA repair before the onset of mitosis. 30 Chk1 is also phosphorylated at Ser280 by the serine/threonine kinase Akt, 31 and recent evidence indicate that RSK also participates in the phosphorylation of this site. 32 Although phosphorylation of this residue is not required for checkpoint function in untransformed cells, 29 it was shown to inhibit Chk1 in PTEN-deficient cells by promoting its ubiquitination and cytoplasmic sequestration.
33
Chk1 phosphorylated on Ser280 fails to undergo activating phosphorylation at Ser345 following DNA damage, 33, 34 presumably because it is inaccessible to its upstream kinase, ATR. Although Chk1 phosphorylation at Ser280 was shown to contribute to genomic instability in cells lacking PTEN, it is currently unknown whether Chk1 regulation contributes to cancer cell chemoresistance.
Herein, we describe a novel link between the Ras/MAPK pathway and the DNA damage response. We demonstrate that RSK1 and RSK2 are the predominant protein kinases that phosphorylate Chk1 on Ser280 in response to mitogens and growth factors. We find that RSK inhibits Chk1 activation in response to DNA damage, and accordingly, we show that RSK promotes G2 DNA damage checkpoint recovery. Our findings suggest that RSK participates in melanoma chemoresistance, and consistently, we find that RSK inhibition sensitizes melanoma cells to DNA-damaging agents.
RESULTS

The Ras/MAPK pathway promotes Chk1 phosphorylation at Ser280
To evaluate whether activation of the Ras/MAPK pathway results in Chk1 phosphorylation, we used a phosphospecific antibody directed against Ser280, a potential RSK target site (Figure 1a) . Notably, we found that potent agonists of the Ras/MAPK pathway, including the phorbol ester phorbol 13-myristate 12-acetate (PMA) and epidermal growth factor (EGF), robustly stimulated Chk1 phosphorylation at Ser280 in HEK293, HeLa and U2OS cells (Figure 1b) . However, activation of Akt, a known regulator of Chk1 phosphorylation at Ser280, 31, 33 by serum or insulin did not significantly promote Ser280 phosphorylation, despite high levels of Akt phosphorylation (Figure 1b) . To further assess the involvement of the MAPK pathway, we used a MEK1/2 inhibitor (U0126) and found that pretreatment of cells with this compound largely prevented PMA-stimulated Chk1 phosphorylation (Figure 1c ). Ser280 lies within an arginine-rich consensus sequence (RPRVTS 280 ), suggesting that basophilic kinases of the AGC family could regulate this site. RSK, MSK and S6K represent three potential AGC-family kinases stimulated by MEK1/2 signalling. 7 Consistent with a role for RSK, we found that the pan-RSK inhibitor BI-D1870 35 completely abolished Chk1 phosphorylation upon PMA stimulation (Figure 1c ). The specificity of this inhibitor has recently been tested against a panel of over 60 protein kinases and was found to be very potent against RSK family members, but also against another Ser/Thr kinase, PLK1. 36 To further show specificity for RSK, we tested a second RSK inhibitor (SL0101) 9 and found similar results (data not shown). To rule out the involvement of S6K, cells were pretreated with the mTORC1 inhibitor rapamycin to block S6K activation. 37 We found that rapamycin treatment did not prevent Chk1 phosphorylation stimulated by PMA treatment (Figure 1c ). The role of MSK was also addressed, but as there are no MSK inhibitors available, 7 we used anisomycin to stimulate MSK activity downstream of the p38 MAPK pathway. Consistent with a role for RSK but not MSK, we found that anisomycin could not stimulate Chk1 phosphorylation at Ser280 despite potent p38 activation (Figure 1d ). We also determined whether Ser280 phosphorylation could occur in response to DNA damage-mediated signalling. We treated cells with camptothecin, which resulted in a strong stimulation of ATR-mediated Ser345 phosphorylation of Chk1, but did not modulate Ser280 phosphorylation (Figure 1e ). Together, these results suggest that mitogens and growth factors promote Chk1 phosphorylation at Ser280 in a MEK1/2-dependent manner that likely involves the RSK family of kinases.
Growth factors promote Chk1 phosphorylation in a PI3K-independent manner To further assess the role of PI3K/Akt signalling in Chk1 phosphorylation, HEK293 cells were pretreated with PI3K (wortmannin) or MEK1/2 (U0126) inhibitors before PMA or insulin stimulation. Although PMA could promote robust Chk1 phosphorylation, we found that insulin did not significantly regulate Ser280 phosphorylation despite the presence of active Akt (Figure 2a) . Moreover, we found that the MEK1/2 inhibitor, but not wortmannin, completely inhibited Chk1 phosphorylation in response to PMA, indicating that the PI3K/Akt pathway does not regulate Chk1 phosphorylation. We also treated cells with increasing concentrations of insulin, or transfected a constitutively activated (CA) form of Akt (myr-Akt), but despite high Akt phosphorylation levels, we did not observe a significant regulation of Chk1 phosphorylation at Ser280 (Figure 2b ). These effects were not specific to one cell type, as we found similar results in HEK293, HeLa and U2OS cells (Figure 1b) . We also generated stable HEK293 cell lines expressing an empty vector or a CA form of PI3K (PIK3CA), but again, did not find that Akt activation led to Chk1 phosphorylation (Figure 2c ). Together, we concluded that RSK may be the predominant kinase that regulates Chk1 in response to growth factors.
RSK is required and sufficient to promote Chk1 phosphorylation in vitro and in vivo RSK1 and RSK2 are the predominant isoforms expressed in HEK293 cells. 38 To further explore a potential role for RSK in Chk1 phosphorylation, we used small interfering RNA (siRNA)-mediated RNAi to specifically reduce their expression. As expected from the inhibitor studies (Figure 1c ), we found that knockdown of RSK1 and RSK2 significantly reduced Chk1 phosphorylation in response to PMA or EGF stimulation ( Figure 3a) . Knockdown of both RSK1 and RSK2 did not further reduce Chk1 phosphorylation compared with knockdown of RSK1 alone, suggesting that RSK1 may be the predominant RSK isoform responsible for Chk1 phosphorylation. The role of RSK as the predominant kinase for Chk1 was further confirmed by generating stable cell lines expressing either a short hairpin RNA (shRNA) against RSK1, RSK2 or a scrambled sequence. As expected from the siRNA data, we found that stable knockdown of RSK1 or RSK2 resulted in an inhibition of Ser280 phosphorylation when cells were treated with either PMA or EGF (Figure 3b ). To further confirm the role of RSK in Chk1 phosphorylation, HEK293 cells were transfected with different RSK isoforms and mutants. Compared with control vector, expression of RSK1-4 significantly increased Chk1 phosphorylation following PMA stimulation ( Figure 3c ). We found that RSK1 expression induced a stronger increase in Chk1 phosphorylation compared with the other RSK isoforms, suggesting that RSK1 is the predominant isoform involved in Chk1 regulation. Moreover, the expression of a CA form of RSK1 induced Chk1 phosphorylation even in the absence of stimulation (Figure 3d ). RSK1 phosphotransferase activity was also found to be required to stimulate Chk1 phosphorylation, as a RSK1 mutant with inactivating mutations in both kinase domains (K112/464R) 39 did not increase Chk1 phosphorylation over the level already stimulated by endogenous RSK activity (Figure 3d ).
To determine whether Chk1 is a direct RSK substrate, we performed in vitro kinase assays with purified proteins. HEK293 cells were transiently transfected with an empty vector, wild-type or a kinase-inactive form of RSK1 and treated with PMA where indicated. Immunopurified RSK1 was then incubated with bacterially purified GST or a GST-Chk1 fusion protein to determine the level of radioactive phosphate incorporation. Although no incorporation of [ 32 P] label was seen in purified Chk1 incubated with unstimulated RSK1 or kinase-inactive RSK1, we found that activated RSK1 robustly increased [ 32 P] incorporation in purified Chk1 (Figure 4a ). Similar results were obtained when kinase assays were performed with purified wild-type RSK1 from cells treated with EGF, but not when cells were pretreated with U0126 ( Figure 4b ). We found that both RSK1/2 were capable of phosphorylating Chk1 in vitro, and treatment with RSK inhibitors (SL0101 or BI-D1870) was found to prevent phosphate incorporation into recombinant Chk1 (Supplementary Figure S1 ). To determine whether Ser280 is the predominant site of incorporation of [
32 P] label, we incubated RSK1 with wild-type Chk1 or an unphosphorylatable mutant at position 280 (S280A). As shown in Figure 4c , the ability of activated RSK1 to promote [ 32 P] incorporation was drastically reduced with the S280A mutant, indicating that this was the predominant RSK-dependent phosphorylation site in Chk1. Similarly, purified wild-type Chk1 or the S280A mutant were incubated with immunoprecipitated RSK1 from HEK293 cells stimulated or not with PMA, and the resulting samples were immunoblotted using a phosphospecific antibody against Ser280. Whereas activated RSK1 promoted [ 32 P] incorporation in wild-type Chk1, we found that mutation of Ser280 dramatically reduced phosphate incorporation (Figure 4d ). Together, these data support the idea that RSK directly phosphorylates Chk1 at Ser280. Oncogenic MAPK signalling promotes Chk1 phosphorylation and inhibition Ras GTPases are often mutated in human cancers to constitutively activate growth signalling cascades, including the MAPK and PI3K pathways. 40 To determine whether oncogenic forms of Ras and its downstream effector kinase MEK1 stimulate Chk1 phosphorylation, HEK293 cells were transfected with active (G12V) and inactive (S17N) mutants of H-Ras (Figure 5a inhibitors, but not PI3K inhibitors completely prevented Chk1 phosphorylation stimulated by activated Ras (Figure 5a ) or MEK1 (Figure 5b) . Importantly, we show that RSK is required for the regulation of Chk1, as phosphorylation of Ser280 was drastically inhibited by RSK inhibitors (Figure 5c ). Melanomas are characterized by the hyperactivation of the Ras/MAPK pathway, 5, 6 and RSK activity was shown to be high in cells derived from this type of cancer. 13 To assess whether Chk1 is constitutively phosphorylated in melanoma cells, we analysed different melanoma cell lines harbouring the B-Raf V600E mutation. Unlike in HEK293, Hela or U2OS cells, we found that basal levels of Chk1 phosphorylation at Ser280 were very high in serum-starved A375 and Colo829 cells (Figure 5d-lane 1) . These cells also displayed high basal ERK1/2 phosphorylation, consistent with the idea that the MAPK pathway, and particularly RSK, regulates Chk1 in these cells. Accordingly, we found that treatment of A375 or Colo829 cells with MEK1/2 (PD184352) or RSK (SL0101) inhibitors completely abrogated Chk1 phosphorylation at Ser280 (Figure 5d ), indicating that RSK is the predominant kinase regulating Chk1 in melanoma. Chk1 phosphorylation at Ser280 was previously found to prevent its phosphorylation and activation by ATR in response to DNA damage. 33, 34 To determine whether RSK affects Chk1 activation, we monitored Chk1 kinase activity and phosphorylation at its ATRregulated site, Ser345. Interestingly, we found that treatment of melanoma cells with MEK1/2 (PD184352) or RSK (SL0101) inhibitors increased Chk1 phosphorylation at Ser345, while completely inhibiting Ser280 phosphorylation (Figure 5d ). Accordingly, we found that inhibition of MEK1/2 or RSK activity resulted in increased endogenous Chk1 kinase activity against cdc25C (Figure 5e ), indicating that RSK constitutively suppresses Chk1 function in melanoma.
RSK facilitates G2 DNA damage checkpoint recovery Next, we examined whether RSK could regulate Chk1-dependent cell cycle arrest in melanoma cells. A375 cells were synchronized in the G2 phase of the cell cycle and then treated for 1 h with a low dose of doxorubicin to activate the G2 DNA damage checkpoint. As shown in Supplementary Figure S2 , treatment of cells with doxorubicin specifically induced gH2AX foci, which label sites of DNA damage. Subsequently, cells were allowed to recover from the DNA damage checkpoint by incubation, after extensive washes, in medium containing protein kinase inhibitors or vehicle ( Figure 6a components of the DNA damage response. To determine whether Chk1 was required for the G2 DNA damage checkpoint, we treated cells with specific Chk1 inhibitors (AZD7762 or PF477736) during checkpoint recovery. As expected, the Chk1 inhibitor abrogated the G2 DNA damage checkpoint induced by doxorubicin treatment (Figures 6d and e; and data not shown). Interestingly, we also found that Chk1 inhibition abrogated the G2 DNA damage checkpoint potentiated by the MEK1/2 and RSK inhibitors ( Figures  6d and e) , suggesting that RSK inhibits Chk1 activity to facilitate checkpoint recovery. Together, these results indicate that RSK modulates the response of melanoma cells to DNAdamaging agents, and thereby, may contribute to melanoma chemoresistance.
Inhibition of RSK sensitizes melanoma cells to DNA-damaging agents To determine whether RSK inhibition potentiates Chk1 activation in response to DNA damage, we treated A375 cells with a RSK inhibitor (SL0101) and two DNA-damaging agents that are currently used in the clinic to treat metastatic melanoma: cisplatin and temozolomide (TMZ). Interestingly, we found that RSK inhibition strongly increased Chk1 activation in response to cisplatin and TMZ, as shown by the phosphorylation of Chk1 at Ser345 (Figures 7a and b) . To assess whether cells treated with RSK inhibitors are more susceptible to DNA-damaging agents, we first identified sublethal concentrations of DNA-damaging agents (cisplatin, DTIC and TMZ) and RSK inhibitor (SL0101) in A375 cells. As reported previously, A375 cells are highly resistant to DNAdamaging agents and their growth was not significantly affected by treatment with high doses of cisplatin (1 mM; Supplementary Figure S3A ), TMZ (100 mM; Supplementary Figure S3B ) and DTIC (3 mM; Supplementary Figure S3C) . Similarly, we found that A375 cells were not affected by a relatively high dose of SL0101 (50 mM; Supplementary Figure S3D) . However, when the RSK inhibitor was combined with DNA-damaging agents, we found a clear synergy between these drugs that resulted in completed inhibition of cell proliferation (Figures 7c-e) . To confirm that these drugs were acting in a synergistic fashion, we determined whether each combination exerted a potentiating effect on melanoma cells compared with expected additive effect. For all three DNAdamaging agents, we found that the maximal effect of the combination treatment was clearly increased compared with the effects seen with single-drug treatment. This effect was particularly evident with TMZ and DTIC, which displayed potentiating factors of 4.32±0.33 and 3.98±0.32, respectively (Figures 7d-e) . To determine whether RSK was promoting the cytotoxic or cytostatic effects of DNA-damaging agents, we performed a FACS analysis of Annexin V binding. Interestingly, we found no evidence of increased apoptosis in cells treated with RSK inhibitors, suggesting that RSK inhibition stabilizes the G2 DNA damage checkpoint. However, we found that A375 cells that stably knockdown RSK1/2 expression are more susceptible to DNAdamaging agents (Figure 7f ), suggesting that RSK may (e) Serum-starved A375 cells were incubated for the indicated time with PD184352 (1 mM) or SL0101 (50 mM), and endogenous Chk1 immunoprecipitated for in vitro kinase activity assays against recombinant GST-cdc25C. Incorporation of radioactive phosphate was quantified using a phosphorImager, and results displayed represent the mean of three independent experiments±s.e.
simultaneously regulate cell survival and proliferation. These results were corroborated by the fact that A375 cells treated with RSK inhibitors are more susceptible to a higher dose of DTIC (30 mM) (Figure 7g ), indicating that RSK inhibition sensitizes melanoma cells to the cytostatic and cytotoxic effects of DNAdamaging agents. Figure 6 . RSK facilitates G2 DNA damage checkpoint recovery. (a) Schematic representation of the experimental workflow. A375 cells were synchronized at the G1/S transition using a double thymidine block, allowed to progress in S phase for 4 h until they reached G2, and then treated for 1 h with doxorubicin (0.25 mM) to induce the G2 DNA damage checkpoint. Doxorubicin was removed and cells were incubated for an additional 18 h in the presence of protein kinase inhibitors before FACS analysis of DNA content. (b) Cells subjected to the protocol described in (a) were incubated with MEK1/2 (1 mM; PD184352) or RSK (50 mM; SL0101) inhibitors during checkpoint recovery. The data presented are representative of at least three independent experiments, and represented in a histogram in c. (d) Same as b, except cells were treated or not with a Chk1 inhibitors (AZD7762) during checkpoint recovery. The data presented are representative of at least three independent experiments, and represented in a histogram in (e).
DISCUSSION
The data presented here indicate that RSK promotes the phosphorylation of Chk1 at Ser280, a site that was previously shown to inhibit Chk1 activation downstream of the PI3K/Akt pathway. 31, 33, 34 Although Akt was found to regulate this site in PTEN-deficient cells, 33, 34 we find that RSK is the predominant Ser280-kinase acting downstream of growth factors and phorbol esters. RSK is also required for Chk1 phosphorylation at Ser280 in cells characterized by the hyperactivation of the MAPK pathway, such as melanoma cells carrying oncogenic BRAF mutations. We find that RSK negatively regulates Chk1 activation induced by DNA damage, resulting in a more rapid recovery from the G2 DNA damage checkpoint. Consistent with these findings, we find that RSK inhibition sensitizes melanoma cells to DNA-damaging agents.
In 2002, the PI3K/Akt pathway was shown to have a key role at the G2/M phase of the cell cycle. 31 Inhibition of PI3K was found to result in Chk1 activation, whereas CA Akt inhibited the ability of Chk1 to become activated in response to DNA damage. Importantly, Akt was shown to directly phosphorylate Chk1 at Ser280, 31 a phosphorylation event that was later shown to trigger ubiquitination and cytoplasmic retention of Chk1. 33 On the basis of the fact that Akt is antagonized by the tumour suppressor PTEN, it was suggested that Akt-mediated phosphorylation and inhibition of Chk1 promotes genomic instability. Although Akt may be involved in Chk1 phosphorylation in cells lacking functional PTEN, our data indicate that RSK is the predominant Ser280-kinase operating downstream of receptor tyrosine kinases, such as the epidermal growth factor receptor, as well as phorbol esters. We found that RSK promotes Chk1 phosphorylation in a PI3K-independent manner (Figure 2) , and that both the RSK1 and RSK2 isoforms are required for this regulation (Figure 3) . Together, our results implicate the Ras/MAPK pathway in the regulation of Figure 7 . RSK inhibition promotes Chk1 activation and melanoma chemosensitivity. (a, b) A375 cells were treated with TMZ (100 mM) or cisplatin (1 mM) for 1 h in the presence or absence of RSK inhibitors (SL0101; 50 mM). Chk1 phosphorylation at Ser280 and Ser345 was monitored by immunoblotting, as well as ERK1/2 phosphorylation and total protein levels of Chk1 and ERK1/2. (c-e) Exponentially growing A375 cells were seeded in 96 well plates in four replicates. After five hours, cells were treated with cisplatin (1 mM), TMZ (100 mM) or DTIC (3 mM) in the presence or absence of SL0101 (50 mM) from 1 to 4 days. Cell proliferation was analysed using the MTS metabolic assay. The asterisk indicates the presence of synergy between drug treatments, as measured with the following formula: Potentiating factor ¼ Effect combination /Effect additive . Data represent one out of three representative independent experiments. (f) A375 cells stably expressing control or RSK1/2 shRNA constructs were seeded as in (c-e) and treated with cisplatin, TMZ or DTIC for 48 hrs. Cells were harvested and apoptotic cell death measured using an Annexin V binding assay. (g) A375 cells were treated with DTIC (30 mM) and SL0101 (50 mM) for 48 hours, and apoptotic cell death was measured as in (f).
Chk1, suggesting a new connection between growth factor signalling and the response to DNA damage.
Our results implicate RSK in G2 DNA damage checkpoint recovery. Although we show that inhibition of MEK1/2 and RSK does not promote G2 arrest in the absence of DNA damage, we find that treatment of cells with MEK1/2 and RSK inhibitors potentiated the G2 DNA damage checkpoint triggered by doxorubicin ( Figure 6 ). These findings implicate the Ras/MAPK pathway in G2 DNA damage checkpoint recovery, and suggest that RSK has a critical role in this process. Moreover, we found that Chk1 inhibition abrogated the G2 arrest potentiated by RSK inhibitors, indicating that RSK negatively regulates Chk1 in response to DNA damage ( Figure 6 ). To demonstrate a role for RSK in checkpoint recovery, we have used well-described MEK1/2 (PD184352) and RSK (SL0101) inhibitors. At the moment, only two small molecules have been described as inhibitors of the N-terminal kinase domain of RSK, SL0101 and BI-D1870, 9, 35 and both have been recommended for cell-based assays. 36 However, BI-D1870 was originally identified in a chemical screen for PLK1 inhibitors, and consistent with this, this compound was shown to have an in vitro IC 50 of 0.1 mM against PLK1. 35, 36 On the basis of the important role of PLK1 in mitosis, 41 these findings indicate that BI-D1870 should not be used to address the role of RSK in cell cycle progression. Moreover, PLK1 is known to regulate Chk1 activation during G2 DNA damage checkpoint recovery, 42, 43 further preventing the use of BI-D1870 to address the role of RSK in Chk1 regulation. 44 Malignant melanomas are known to be highly resistant to chemotherapeutic compounds and the molecular mechanisms underlying chemoresistance is likely to be very complex. 45, 46 Complicating drug development, melanoma cells accumulate several genetic changes with the potential to promote proliferation, evade senescence and apoptotic cell death. Our results indicate that cells carrying an activated BRAF allele constitutively inhibit Chk1 function ( Figure 5 ). Indeed, we found that RSK inhibition rescues Chk1 activity in melanoma cells, suggesting that RSK contributes to the poor response of melanoma cells to DNAdamaging agents. We found that RSK inhibition potentiates Chk1 activation and cell cycle arrest in response to cisplatin, TMZ and DTIC, providing an important proof of principle that targeting RSK may be a valuable approach to decrease melanoma chemoresistance.
MATERIALS AND METHODS
Cell culture, transfection and plasmid constructs HEK293, HeLa, U2OS and A375 cells were maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum (FBS). Colo829 cells were grown in RPMI medium with similar supplements. HEK293 cells were transfected using calcium phosphate as described previously. 47 Cells were grown for 24 h following transfection and starved of serum, where indicated, for 16-18 h. Starved cells were pretreated with various inhibitors, where indicated, for 30 min before stimulation. Wortmannin, cisplatin, DTIC and TMZ were purchased from Sigma Aldrich (St Louis, MO, USA). U0126, rapamycin, PMA were purchased from Biomol (Plymouth Meeting, PA, USA). PD184352 and SL0101 were purchased from Selleck Chemicals and Toronto Research Chemicals (Toronto, ON, Canada), respectively. Insulin and EGF were purchased from Invitrogen (Life Technologies, Carlsbad, CA, USA). The plasmids encoding HA-tagged RSK1-4 were previously described. 47, 48 The pGEX-Chk1 was generated by inserting nucleotides 250-300 of human Chk1 in pGEX-4T, and recombinant fusion proteins were purified from BL-21 bacteria, as done previously. 49 The vectors encoding Flag-MEK1-DD, RasG12V and Ras S17N were previously described, 47 and the pGEX-cdc25C construct was a kind gift from Dr Yolanda Sanchez (Dartmouth Medical School).
Antibodies
Antibodies targeted against phospho-rpS6 (Ser235/236), phospho-Akt (Ser473), Akt, ERK1/2, pan-RSK1/2/3, phospho-p38 (Thr180/Tyr204) and phospho-Chk1 (Ser280, Ser345) were purchased from Cell Signalling Technologies (Danvers, MA, USA). Anti-phospho-ERK1/2 and anti-HA monoclonal antibodies were purchased from Sigma Aldrich. Anti-RSK1, RSK2 and Chk1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Invitrogen, respectively. The phospho-RSK (Ser380) antibody was purchased from R&D Systems (Minneapolis, MN, USA). All secondary horseradish peroxidase-conjugated antibodies used for immunoblotting were purchased from Chemicon (Temecula, CA, USA).
Immunoprecipitations and immunoblotting
Cell lysates were prepared as described previously. 47 For immunoprecipitations, cell lysates were incubated with the indicated antibody for 2 h, followed by 1 h of incubation with protein A-Sepharose CL-4B beads (GE Healthcare, Piscataway, NJ, USA). Immunoprecipitates were washed three times in lysis buffer and, along with total cell lysates, were subjected to SDS-PAGE and electroblotted onto polyvinylidene difluoride membranes for immunoblotting.
Protein phosphotransferase assays
For RSK1/2 and Chk1 kinase assays, beads from immunoprecipitations were washed twice in lysis buffer and twice in kinase buffer (25 mM Tris-HCl (pH 7.4), 10 mM MgCl 2 , 5mM b-glycerophosphate). Kinase assays were performed with bacterially purified recombinant GST-Chk1 or GST-cdc25C fusion proteins (3 mg per assay) as substrate, under linear assay conditions. Assays were performed for 10 min at 30 1C in kinase buffer supplemented with 5 mCi [g- 
RNA interference and viral infections
For siRNA-mediated knockdown of RSK1 and RSK2, validated 21-nucleotide cRNAs with symmetrical two nucleotide overhangs were obtained from QIAGEN (Valencia, CA, USA). HEK293 cells were transfected using calcium phosphate and 50 nM siRNA per dishes. At 24 h following transfection, cells were serum-starved overnight before being harvested. For shRNAmediated knockdown, lentiviruses were produced using vectors from the Mission TRC shRNA library. Cells were infected in the presence of 4 mg/ml polybrene, and 2 days after viral infection, cells were treated and selected with 2 mg/ml puromycin. shRNA constructs were obtained from Sigma Aldrich (shRSK1, TRCN470; shRSK2, TRCN537).
Proliferation assays
For proliferation assays, cells were grown in media supplemented with 5% fetal bovine serum in the presence of inhibitors. The relative number of viable cells was measured every 24 h during 4 consecutive days using the MTS cell proliferation assay from Promega (Madison, WI, USA), as shown elsewhere. 49 Absorbance was measured at 490 nm using a Tecan GENios Plus microplate reader (Männedorf, Switzerland) and results displayed represent the mean of triplicates ± s.e.
Synchronization and flow cytometric analysis of cell cycle distribution A375 cells were synchronized at the G1/S transition with a double thymidine block. Twenty-four hours after being seeded, cells were exposed to 2 mM thymidine (Sigma Aldrich) for 16 h. Cells were then released for 6 h followed by a second thymidine block for a further 16 h. Four hours after release from the thymidine block, the G2 DNA damage checkpoint was activated by treating cells with 0.25 or 0.125 mM doxorubicin (EMD Millipore, Lake Placid, NY, USA) for 1 h. Doxorubicin was washed thoroughly and immediately after washing, PD184352 (5 mM) or SL0101 (50 mM) was added to the culture medium with or without PF477736 (0.2 mM; Sigma Aldrich) or AZD7762 (0.3 mM; Selleck Chemicals) and incubated for 18 h. The DNA and RNA intercalating fluorescent dye propidium iodide (Sigma Aldrich) was used to quantify cellular DNA content and cell cycle distribution. After treatment, A375 cells were harvested and fixed in 95% ethanol at À 20 1C. Before analysis, cells were incubated with RNase A (100 mg/ml; Sigma Aldrich) and stained with propidium iodide (40 mg/ml) for 30 min. Samples were immediately analysed by flow cytometry with a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA) at low flow rate. A total of 2 Â 10 4 events were recorded per sample, and the cell fraction G0/G1, S and G2/M phases were quantified with BD FACSDiva software (BD Biosciences).
